CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Acute Lymphoblastic Leukemia|
|Funding Request||Individuals, aged 1–30 years, newly diagnosed with intermediate- or high-risk (CNS1 or CNS 2) T-ALL, stages II-IV, during upfront therapy.|
|Clarification||Pediatric Oncology Group of Ontario has notified pCODR that they will not be filing the submission.|
|Pre Noc Submission||No|
|NOC Date||July 31, 2015|
|Manufacturer||Novartis Pharmaceuticals Canada Inc.|
|Sponsor||Pediatric Oncology Group of Ontario|
|Submission Date (Target Date)|
|Clarification||The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has not been provided.|
|Stakeholder Input Deadline (target date based on target submission date) ‡|
|Check-point meeting (target date)|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.